VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company’s flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia. The study is already ongoing at several clinical sites in the United States, Canada, Poland and India. The total study is expected to enroll about 880 head and neck cancer patients in about 48 hospitals in 9 countries on three continents. CEL-SCI’s partners Teva Pharmaceuticals and Orient Europharma will conduct parts of the Phase III study in Israel and Taiwan respectively.
